Ngomhla we-10 kweyoMdumba, ngo-2025, iCARsgen Therapeutics ibhengeza ukuba umntu wokuqala onyangwe ngonyango lwe-allogeneic BCMA CAR-T oluphuhliswe kwiqonga le-THANK-u Plus™, ufumene impendulo epheleleyo (sCR) kunye ne-minimum residue disease (MRD) negativity kuvavanyo lwe-Day-28. Iphuhliswe ngaphakathi, iqonga le-THANK-u Plus™ yitekhnoloji entsha ye-allogeneic CAR-T eyilelwe ukoyisa imingeni yokufikeleleka kunyango lwe-CAR-T.
Isigulana, esafunyaniswa sine-relapse/refractory multiple myeloma, uhlobo lwe-IgA-λ (R-ISS Stage II), ngaphambili sasifumene iindlela ezintathu zonyango oludibeneyo kunye nokufakelwa kwe-autologous hematopoietic stem cell. Emva kokuqhubela phambili kwesifo emva konyango lwamva nje, isigulana sabhaliswa kwisilingo seklinikhi. Emva kokufakwa kweeseli ze-CAR T kwinqanaba ledosi eliphantsi ngokwemigaqo yeklinikhi, isigulana safumana i-Grade 1 cytokine release syndrome (CRS), eyalawulwa ngempumelelo nge-antipyretics kunye ne-tocilizumab, kwaye isigulana asizange sibonise i-immune effector cell-associated neurotoxicity syndrome (ICANS) okanye ezinye iziganeko ezingalunganga ezinxulumene ne-CAR-T, nto leyo ebonisa iprofayili yokhuseleko oluhle ngokubanzi.
Olu nyango lwe-CAR-T lwenzelwe unyango lwe-relapse/refractory multiple myeloma (R/R MM) kunye ne-relapse/refractory plasma cell leukemia (R/R PCL). Uhlaziyo olongezelelweyo lwedatha lulindeleke kwisiqingatha sesibini salo nyaka.
Okwangoku, kusekho iimvavanyo ezininzi zeklinikhi zobuchwepheshe obutsha bokulwa nomhlaza eTshayina obufuna izigulane. Iingcebiso ngamayeza amatsha kunye nobuchwepheshe, ungaqhagamshelana neSebe leMicimbi yeZibhedlele ze-Oncology zaseBeijing South Region.
Inombolo yefowuni: 4008803716
Email：myimmnet@163.com
Iireferensi
2.https://www.prnasia.com/
Ixesha leposi: Feb-11-2025